Table 1.
Patient characteristics and outcomes by age group
| No. (%) or Median (range) | P | |||
|---|---|---|---|---|
| Age 15–44 [n=197] | Age 45–64 [n=222] | Age 65–84 [n=64] | ||
| Median age, year (range) | 36 (15·1–44·9) | 53 (45·1–64·9) | 70 (65·2–84·8) | - |
| Male, No. (%) | 125 (63) | 124 (56) | 38 (59) | 0·29 |
| Ethnicity, No. (%) | ||||
| Caucasian | 153 (78) | 171 (77) | 62 (97) | 0·028 |
| African-American | 12 (6) | 16 (7) | 1 (2) | |
| Hispanic | 23 (12) | 24 (11) | 1 (2) | |
| Asian | 4 (2) | 9 (4) | 0 | |
| Other | 5 (3) | 2 (1) | 0 | |
| Median follow-up, months (range) [IQR] | 94 (2–154) [47–120] | 89 (4–153) [43–122] | 121 (5–148) [44–128] | 0·87 |
| Sokal risk score, No. (%) | ||||
| Low | 156 (79) | 161 (73) | 18 (28) | <0·0001 |
| Intermediate | 28 (14) | 49 (22) | 39 (61) | |
| High | 13 (7) | 12 (5) | 7 (11) | |
| Initial TKI, No. (%) | ||||
| Imatinib | 113 (57) | 116 (52) | 42 (66) | 0·32 |
| Nilotinib | 42 (21) | 50 (23) | 13 (20) | |
| Dasatinib | 42 (21) | 56 (25) | 9 (14) | |
| Clonal evolution at diagnosis, No. (%) | 7 (4) | 7 (3) | 6 (9) | 0·077 |
| Diagnosis to treatment, day (range) | 26 (0–377) | 28 (1–215) | 24 (0–122) | 0·33 |
| Cumulative response to TKI within 1 year, No. (%) | ||||
| CCyR | 165 (84) | 202 (91) | 58 (91) | 0·059 |
| MMR | 136 (69) | 169 (76) | 44 (69) | 0·31 |
| MR4·5 | 62 (31) | 75 (34) | 25 (39) | 0·56 |
| CMR | 34 (17) | 40 (18) | 10 (16) | 0·91 |
| Overall cumulative response to TKI , No. (%) | ||||
| CCyR | 171 (87) | 207 (93) | 59 (92) | 0·077 |
| MMR | 152 (77) | 183 (82) | 52 (81) | 0·44 |
| MR4·5 | 127 (64) | 158 (71) | 47 (73) | 0·24 |
| CMR | 91 (46) | 124 (56) | 33 (52) | 0·16 |
| 5-year OS, % (95% CI) | 96 (93·2–99·2) | 94 (89·9–97·1) | 80 (69·5–90·7) | <0·0001 |
Abbreviations: TKI, tyrosine kinase inhibitor; CCyR, complete cytogenetic response; MMR, major molecular response; MR4·5, molecular response with 4·5 log reduction by international scale; CMR, complete molecular response; OS, overall survival; CI, confidence interval; IQR, interquartile range.